Effect of Metformin and Valsartan Toward Homa-IR in Metabolic Syndrome Patient with Non-Alcoholic Fatty Liver Disease (NAFLD)

https://doi.org/10.22146/actainterna.48403

Prasetio Kirmawanto(1*), Siti Nurdjanah(2), Muhammad Robikhul Ikhsan(3)

(1) 
(2) 
(3) 
(*) Corresponding Author

Abstract


ABSTRACT

Background: Insulin sensitizer drugs such as metformin has suggested giving in metabolic syndrome patient and NAFLD, which both pathogeneses were insulin resistance. Angiotensin II receptor blocker (ARB), anti-hypertension drugs, has the similar properties to improve regulation of Proliferator-Activated Receptor Gama (PPARɤ). This aim of the study is to prove the improvement of insulin resistance which examined by HOMA-IR method on metabolic syndrome patient with NAFLD after receiving metformin and valsartan medication.

Method: This study was conducted to the patient in Endocrinology Clinic Sardjito General Hospital aged 35-36 years who meet diagnostic criteria for metabolic syndrome based on the IDF in 2006 and NAFLD. Convenience sampling method is done for 11 months (May 2012 – March 2013) and was expected sample size 35. HOMA-IR examination made before and after administration of metformin and valsartan for 12 weeks. Cut off value for HOMA –IR on pathological metabolic syndrome and NAFLD was ≥ 2. Medical and Health Research Ethics Committee (MHREC) Faculty of Medicine Universitas Gadjah Mada approved this study protocol.

Result: Subject of study retrieved 15 (43%), six males (40%) and nine females (60%) aged 43-63 years old. Median HOMA-IR baseline was 2.8 (0.6-14.5) and at the end of therapy was 3.8 (1.72-14.1). Eleven (74%) have increased HOMA-IR value and four (26%) experience declined but none of them reach the value below 2. In general clinical improvement occurs in the form of AST and ALT reduction but not statistically significant.

Conclusion: This study does not prove that administration of metformin and valsartan in-patient with metabolic syndrome with NAFLD would improve insulin resistance assessed by the HOMA-IR method.

Keywords: Metformin, valsartan, metabolic syndrome, NAFLD, HOMA-IR

 


Keywords


Metformin, valsartan, metabolic syndrome, NAFLD, HOMA-IR

Full Text:

PDF


References

Paschos, P., Paletas, K., 2009. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9–19.

Smits, M.M., Ioannou, G.N., Boyko, E.J., Utzschneider, K.M., 2013. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 28, 664–670.

Bugianesi, E., McCullough, A.J., Marchesini, G., 2005. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42, 987–1000.

Chavez-Tapia, N.C., Barrientos-Gutierrez, T., Tellez-Ávila, F.I., Sánchez-Ávila, F., Montaño-Reyes, M.A., Uribe, M., 2006. Insulin sensitizers in the treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol 12, 7826–7831. doi:10.3748/wjg.v12.i48.7826

Caldwell, S.H.M., Argo, C.K.M., Al-Osaimi, A.M.S.M., 2006. Therapy of NAFLD: Insulin Sensitizing Agents. Journal of Clinical Gastroenterology 40, S1–S72.

Hirose, A., Ono, M., Saibara, T., Nozaki, Y., Masuda, K., Yoshioka, A., Takahashi, M., Akisawa, N., Iwasaki, S., Oben, J.A., Onishi, S., 2007. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375–1381.

Enjoji, M., Kotoh, K., Kato, M., Higuchi, N., Kohjima, M., Nakashima, M., Nakamuta, M., 2008. The therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: A pilot study. International Journal of Molecular Medicine 22, 521–527.

Dahlan, M.S., 2010. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan, Seri Evidence Based Medicine 2. Salemba Medika, Jakarta.

Ervin, R.B., 2009. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 1–7.

International Diabetes Federation, 2006. Metabolic Syndrome [WWW Document]. International Diabetes federation. URL http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (accessed 10.27.15).

Wallace, T.M., Levy, J.C., Matthews, D.R., 2004. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495.

Owen, W.E., Roberts, W.L., 2004. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin. Chem. 50, 257–259.

Li, Q., Qu, H.-Q., Rentfro, A.R., Fisher-Hoch, S.P., McCormick, J.B., 2011. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PLoS ONE 6, e21041.

Purnamasari, D.,& Soegondo,S., 2014. Sindrom Metabolik. In: Setiati, S, Alwi. I, Sudoyo, A.W., Simadibrata, M., Setiyohadi, B., Syam, A.F,. eds.Buku Ajar Ilmu Penyakit Dalam Edisi VI Jilid I. Jakarta : Interna Publishing Pusat Penerbitan Ilmu Penyakit Dalam



DOI: https://doi.org/10.22146/actainterna.48403

Article Metrics

Abstract views : 72 | views : 16

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Acta Interna: The Journal of Internal Medicine

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Acta Interna The Journal of Internal Medicine Indexed by:

 

 Indonesia Onesearch Google Scholar IPI Indonesian Publication Index

 website statistics View My Stats  

 

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.